Maximum quantity allowed is 999
Please select the quantity
CAS RN: 366017-09-6 | Product Number: M3058
Mubritinib
×
![]()
×
Purity: >98.0%(HPLC)
Synonyms:
- (E)-4-[[4-[4-(1H-1,2,3-Triazol-1-yl)butyl]phenoxy]methyl]-2-[4-(trifluoromethyl)styryl]oxazole
- TAK 165
Product Documents:
| Size | Unit Price | Shanghai | Tianjin | Japan* |
|---|---|---|---|---|
| 25MG |
¥550.00
|
1 | Contact Us | 3 |
| 100MG |
¥2,055.00
|
Contact Us | Contact Us | 9 |
* For order or inquiry, please contact
Our Authorized Distributors.
*TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.
* To send your quote request for bulk quantities, please click on the "Request Bulk Quote" button. Please note that we cannot offer bulk quantities for some products.
| Product Number | M3058 |
| Purity / Analysis Method | >98.0%(HPLC) |
| Molecular Formula / Molecular Weight | C__2__5H__2__3F__3N__4O__2 = 468.48 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Refrigerated (0-10°C) |
| Condition to Avoid | Heat Sensitive |
| CAS RN | 366017-09-6 |
| Reaxys Registry Number | 13498857 |
| PubChem Substance ID | 354335238 |
| MDL Number | MFCD09954135 |
Specifications
| Appearance | White to Gray to Brown powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Melting point | 158.0 to 162.0 °C |
| NMR | confirm to structure |
Properties (reference)
| Melting Point | 160 °C |
GHS
Related Laws:
Transport Information:
| Customs Control Conditions (Q) |
Application
ヒト上皮成長因子受容体2 (HER2) チロシンキナーゼ阻害剤，ムブリチニブ
Small-molecule protein kinase inhibitors are widely used to elucidate cellular signaling pathways. Mubritinib (TAK 165) is a selective inhibitor of the human epidermal growth factor receptor 2 (HER2) tyrosine kinase. Reportedly, mubritinib specifically inhibits HER2 tyrosine kinase IC50 6 nmol/L and do not inhibit other types of tyrosine kinase up to 25,000 nmol/L.1) Several reports suggest HER2 expression in bladder cancer, renal cell carcinoma (RCC) and androgen-independent prostate cancer. However, the clinical development program for mubritinib as an anti-cancer drug was discontinued. (The product is for research purpose only.)
References
- 1)Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo
- 2)Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity
PubMed Literature
Articles/Brochures
TCIMAIL
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.